Nefazodone: Structure, mode of action and pharmacokinetics

Journal of Psychopharmacology

Volumn 10, Issue SUPPL. 1, 1996, Pages 1-4

  Malik, Kemal ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antidepressant; Dosing; Indications; Mode of action; Nefazodone; Pharmacokinetics

Indexed keywords

ANTIDEPRESSANT AGENT; DRUG METABOLITE; NEFAZODONE; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ANTICHOLINERGIC EFFECT; ANXIETY; ARTICLE; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SEROTONIN UPTAKE; SLEEP DISORDER; SYNAPSE;

EID: 0029949872     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119601000101     Document Type: Article

References (19)

1. Arnott S, Nutt D J (1994) Successful treatment of fluvoxamine-induced anorgasmia by cyproheptadine. Br J Psychiatr 164: 838-839
2. Cusack B, Nelson A, Richelson E (1994) Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 114: 559-565
3. Davis J M (1995) A comparative evaluation of the SSRIs, venlafaxine, and nefazodone. Directions Psychiatr 15: 1-8
4. Delgado P L, Price L H, Miller H L, Salomon R M, Aghajanian G K, Heninger G R, Charney D S (1994) Serotonin and the neurobiology of depression. Arch Gen Psychiatr 51: 865-874
5. Dubovsky S L, Thomas M (1995) Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatr 56 (suppl 2): 38-48
6. Eison A S, Eison M S, Torrente J R,Torrente J R, Wright R N. Yocca F D (1990) Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 26: 311-315
7. Fontaine R, Ontiveros A, Elie R, Kensler TT, Roberts DL, Kaplita S, Ecker JA, Fahidi G (1994) A double-blind comparison of nefazpdone and imipramine and placebo in major depression. J Clin Psychiatry 55:234-241
8. Franc J E, Duncan G F, Farmen R H, Pittman K A (1991) High performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics. J Chromatogr Biomed Appl 570: 129-138
9. 2 receptors in rat brain: an autoradiographic study. Synapse 14: 324-331
10. Mendels J, Reimherr F, Marcus RN, Roberts DL, Francis RJ, Anton SF (1995) A double-blind, placebo-controlled trial of two-dose ranges of nefazodone in the treatment of depressed outpatients. J Clin Psych 56 (Suppl 6): 30-36
11. Preskorn S H, Burke M (1992) Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatr 53 (Suppl 9): 5-1
12. Rickels K, Schweizer E, Clary C, Fox I, Weise C (1994) Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 164: 802-805
13. Roy A, Vikkunen M, Linnoila M (1990) Serotonin in suicide, violence and alcoholism. In Coccero E F, Murphy D L (eds), Serotonin in major psychiatric disorders. American Psychiatric Press, Washington, DC
14. Schätzberg A F (1992) Recent developments in the acute somatic treatment of major depression. J Clin Psychiatr 53 (Suppl 3): 20-25
15. Schildkraut J J (1965) Catecholamine hypothesis of affective disorder. Am J Psychiatr 112: 509-522
16. Sleight A J, Pierce PA, Schmidt A W et al. (1991) The clinical utility of serotonin receptors active agents in neuropsychiatric disease. In Peroutka S J (ed.), Serotonin receptor subtypes: basic and clinical aspects. Wiley-Liss, New York, pp. 211-227
17. Stahl S M, Frakes D C (1995) Nefazodone and the serotonin receptor modulators: a new member of a unique class of antidepressant agents. Int Rev Psychiatr 7: 29-39
18. Sussman N (1994) The potential benefits of serotonin receptor-specific agents. J Clin Psychiatr 55 (Suppl): 45-51
19. Taylor D, Carter R, Eison A, Mullins V, Smith H, Torrente J, Wright (1995) Pharmacology and neurochemistry of nefazodone, a novel antidepressant. J Clin Psychiatr 56 (Suppl): 3-12